According to filings with the U.S. Securities and Exchange Commission, Galenus Precision Pharmacy is raising up to $6,599,999.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Galenus Precision Pharmacy
GalenusCare is the trusted precision pharmacy partner for enhancing quality in PACE and hospice care. Our Precision Pharmacists collaborate closely with care teams to optimize medication regimens and prevent adverse drug eventsimproving outcomes, reducing medical costs, and easing staff burden. Backed by advanced clinical science, AI, and collaborative practice efficiencies, we deliver personalized, end-to-end medication management within streamlined pharmacy workflows.

To learn more about Galenus Precision Pharmacy, visit https://galenuscare.com/
Galenus Precision Pharmacy Linkedin Page: https://www.linkedin.com/company/galenuscare/

Contact:
Calvin Knowlton, President
844-425-3687
https://www.linkedin.com/in/drcalvinknowlton/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.